Hallux Inc

Hallux Inc is an innovative specialty pharmaceutical company focused on developing safe and highly effective breakthrough solutions for common infections of the toe, nail, and foot. The company's lead therapeutic candidate, Hallux Subungual Gel (HSG), is a novel terbinafine topical dosage form designed for treating toenail fungus, the most common nail disorder seen by podiatrists and dermatologists. The product is set to commence a Phase 2 efficacy, tolerability, and PK study in more moderately infected patients enrolled from OrthoArizona, a premier foot and ankle institute serving the greater Phoenix area. It is estimated that Podiatrists treat over 7 million patients a year for toenail fungus using routine nail debridement and Rx/OTC topicals, none of which work very well. Hallux aims to provide patients a cure rate exceeding oral terbinafine without systemic risk or the burden of daily pills for many months. Founded in 2012 and headquartered in the United States, Hallux Inc recently received a $9.40M Venture Round investment on 13 April 2022. The company is focused on achieving FDA and global registration of HSG and providing patients with highly effective topical therapy to cure fungal infections that have plagued many people worldwide for years. With a focus on Biotechnology and Health Care, Hallux Inc presents a promising investment opportunity in the pharmaceutical sector.